Citeline Podcasts

Norstella
Norstella

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

  1. 1d ago

    Drug Fix: MFN Finds Mid-Size Companies And More Vaccine Policy Moves

    Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential differences between Most Favored Nation drug pricing agreements for small and mid-size companies and the largest pharmas (1:03), as well as the impact of potential vaccine policy changes on the US public health apparatus (15:10).  More On These Topics From The Pink Sheet MFN Deal Impact Unclear As White House Ready To Announce Agreements With Mid-Size Pharmas: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/mfn-deal-impact-unclear-as-white-house-ready-to-announce-agreements-with-mid-size-pharmas-ECRFYU4TOVBSPG63U26CWI5FIM/ HHS Builds A Legal Firewall Around Its Next Vaccine Moves With RFI On Federal Categories: https://insights.citeline.com/pink-sheet/vaccines/hhs-builds-a-legal-firewall-around-its-next-vaccine-moves-with-rfi-on-federal-categories-5HILL2G52BE3PI5BJTJ4UZ76RI/

    Drug Fix: MFN Finds Mid-Size Companies And More Vaccine Policy Moves

  2. 1d ago

    【3分で解説 #世界のファーマ】第30回　米国、ジェネリック関税に国内外から懸念／BMSとAZ合併の噂 (Japanese-language podcast) Aug. 28, 2026

    世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら. As US Threatens A Tariff Bomb On Generic Drugs, Will Exemptions Be Negotiated? https://insights.citeline.com/pink-sheet/policy-regulation/as-us-threatens-a-tariff-bomb-on-generic-drugs-will-exemptions-be-negotiated-6NUJIGIPNFCT5HRSSIEIXJSJZY/  Trump Tariff Action On Generics Highlights Temporary Nature Of Exemptions https://insights.citeline.com/scrip/business/strategy/trump-tariff-action-on-generics-highlights-temporary-nature-of-exemptions-GJOW5MWMOJBKLEWSDMM222DTYI/  Trump’s Generic Tariff Clock Demands Compression Of US FDA Review Timelines https://insights.citeline.com/pink-sheet/biosimilars-and-generics/trumps-generic-tariff-clock-demands-compression-of-us-fda-review-timelines-5C4DXMVVCRGRRGXG2QRUH62GTQ/  BMS Likely Main APAC Beneficiary Of Any AstraZeneca Mergerhttps://insights.citeline.com/scrip/business/deals/bms-likely-main-apac-beneficiary-of-any-astrazeneca-merger-NVNVSZTPHFBAXHZR6H6IPI35JU/   ※全文の閲覧には購読（有料）が必要です。世界の製薬ビジネスメディアScrip（スクリップ）とは？https://www.citeline.com/ja-jp/products-services/commercialization/scrip

  3. 4d ago

    Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends

    A videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath, EU, Europe

  4. 6d ago

    Drug Fix: What FDA Commissioner Nominee Heidi Overton Will Mean For The Agency

    Pink Sheet Editor-in-Chief Nielsen Hobbs, executive editor Derrick Gingery, and senior reporter Maaisha Osman discuss new FDA commissioner nominee Heidi Overton, her prospects for confirmation, and what her pick means for the agency. More On The Topic From The Pink Sheet FDA Commissioner Nominee Has The White House’s Trust. Winning Over Career Staff Is Another Matter: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/fda-commissioner-nominee-has-the-white-houses-trust-winning-over-career-staff-is-another-matter-IIZWK46CFVHMBIZF5XM7L4PQ6U/ Trump To Nominate White House Advisor Overton As FDA Commissioner: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/outgoing-georgia-congressman-buddy-carter-eyed-for-fda-commissioner-RHIYQUYTIVGRTFEXYCHCWPG54Y/

    Drug Fix: What FDA Commissioner Nominee Heidi Overton Will Mean For The Agency

  5. Aug 21

    Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment

    One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials - could finally change that.

    Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment

  6. Aug 17

    Strategic Intent: The Rise Of Mid-Cap Dealmakers

    Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs.

  7. Aug 17

    Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp

    Everyone in consumer health is talking about GLP-1s. While this new generation of weight loss drugs is firmly on the prescription-only side, industry is now thinking about how it can meet users’ needs for products that address side effects and the nutritional gaps that come with rapid weight loss. In this episode of HBW Insight’s Over the Counter, ALL Creative founder Beverley Law and consultant Martina Gripp – who has 25 years’ experience in industry including at Boehringer Ingelheim and Perrigo – unpick what a companion products category actually requires. We talk claims and the grey area around referencing a prescription brand, the difference between a product marketed for GLP-1 users and one that ends up being used by them, what a real evidence investment looks like from bibliographic data through to a clinical trial, and what OTC companies should be doing right now. A quick update for our listeners: HBW Insight now has its own dedicated podcast channel. To stay up to date on the latest, follow HBW Insight’s Over The Counter podcast on Spotify and Apple Podcast. You'll find the link in this episode's description. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com

    Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp

  8. Aug 14

    Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name Change

    Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the important provisions of the new prescription drug and generic drug user fee commitment letters (:53), including the revenue cut coming in PDUFA VIII (7:16), as well as the new formal meeting names (13:53) and “America First” incentives (23:47) in GDUFA IV. More On These Topics From The Pink Sheet US FDA Will Start PDUFA VIII Collecting Less Revenue, But Will Fees Drop?: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/us-fda-will-start-pdufa-viii-collecting-less-revenue-but-will-fees-drop-3VJC34BDRZFHHMY5N5YIODQRZ4/ Generic Drug User Fee Deal Creates Domestic-Focused Incentives, Could Lower Application Fees: https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/generic-user-fee-deals-creates-domestic-focused-incentives-could-lower-application-fees-UOG7BGF2YNA3NMWHLFMM2C2BFU/ Generic Drug User Fee Agreement Streamlines Meetings, Creates ‘Complex Issue’ Goal Extension: https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/generic-drug-user-fee-agreement-streamlines-meetings-creates-complex-issue-goal-extension-TZFGYWV2VNCF3M7GJWPOJZ66SI/

    Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name Change
See All (632)

4.2
out of 5
30 Ratings

About

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Information

  • Channel
    Norstella
  • Creator
    Norstella
  • Years Active
    2014 - 2026
  • Episodes
    632
  • Rating
    Clean
  • Copyright
    © 24c12740-34d6-11f1-9889-f71e988e8a77
  • Show Website
    Citeline Podcasts

More From Norstella

You Might Also Like